1730. Outcomes of Patients With Detectable Cytomegalovirus (CMV) DNA at Randomization in the Double-blind, Placebo-Controlled Phase 3 Trial of Letermovir (LET) Prophylaxis for CMV-Seropositive Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients

BACKGROUND: LET prophylaxis through HCT Week 14 was highly effective in preventing clinically significant CMV infection (CS-CMVi), had a good safety profile, and was associated with lower all-cause mortality by HCT Week 24 compared with placebo (PBO). Patients with detectable CMV DNA at randomizatio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Autores principales: Marty, Francisco M, Ljungman, Per, Chemaly, Roy F, Wan, Hong, Teal, Valerie L, Butterton, Joan, Yeh, Wendy W, Leavitt, Randi Y, Badshah, Cyrus
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6252851/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy209.136
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares